XLV · XLV
Price
Snapshot
50 fields · last close| Market Cap | — |
| P/E | — |
| Float | — |
| Beta | 0.55 |
| Volatility | 13.7% |
| Exchange | — |
| Sector | — |
| Cap tier | — |
| Macro sensitivity | Low |
| Clavix score | 85 |
| Price | 171.62 |
| Change | −0.95% |
| Prev Close | 173.26 |
| Open | 174.07 |
| Day Low | 171.38 |
| Day High | 174.16 |
| Avg Vol | 7 |
| Avg $ Vol | $1.24B |
| 52W High | 176.59 |
| 52W Low | 133.72 |
| 52W Pos | 88.4% |
| From High | −2.82% |
| From Low | +28.34% |
| Max DD 1Y | −10.84% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +0.35% |
| SMA 50 | +3.75% |
| SMA 200 | +10.53% |
| RSI (14) | 61.2 |
| Vol 30D | 17.9% |
| Vol 90D | 17.9% |
| 1Y Range | 134–177 |
| Daily bars | 506 |
| Perf Week | +0.98% |
| Perf Month | +5.54% |
| Perf Quarter | +13.93% |
| Perf Half Y | +12.57% |
| Perf Year | +26.55% |
| Perf YTD | +10.36% |
| Prev Day | −0.95% |
| Clavix | A |
| Debt / Eq | — |
| Curr Ratio | — |
| Int Cover | — |
| FCF Margin | — |
| Rev Growth | — |
| Profit | Mixed |
| Leverage | Moderate |
| Sector rank | — |
What XLV does
XLV is an equity ETF with a total of 63 individual holdings. The top holdings are Eli Lilly and Company stock at 16.71%, Johnson & Johnson at 10.69%, AbbVie at 7.72%, UnitedHealth Group at 6.55%, and Merck & Co. at 5.49%.
Clavix risk grade
regraded every trading dayXLV grades A, 85 of 100. Steadiest on Price Stability (72), most exposed on News Sentiment (56, mixed). 2 of the 4 weighted dimensions sit above the all-names median.
How rough the ride is
| XLV | |
|---|---|
| Betavs the overall market · lower is steadier | 0.55 |
| Volatilityannualized | 13.7% |
| Max drawdown, past yearworst peak-to-trough fall | −10.8% |
| Typical daily movemedian absolute daily change | 0.60% |
| Days beyond ±3%of the last 252 sessions | 42% |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| XLV | |
|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.55 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| XLV | |
|---|---|
| 1 week | +1.0% |
| 1 month | +5.5% |
| Year to date | +10.4% |
| 1 year | +26.6% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| XLV | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 18 Feb |
| Average score0 most bearish, 100 most bullish | 57 |
| Bullish · bearisharticles above 60 · below 40 | 15 · 5 |
| Directionarticles whose tone is improving vs worsening | 14 ↑ 5 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Growth
| XLV | |
|---|---|
| Revenue growthyear over year | — |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the all-names median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openAn article compares XLV, a healthcare ETF, against BlackRock Health Sciences Trust (BME) and argues XLV is the better option for investors. It claims XLV has delivered higher total returns and better preservation of NAV (net asset value per share) than BME over 5- and 10-year periods, while BME's recent gains came from a shrinking discount to NAV rather than stronger management.
Moderna's stock rose more than 140% in its best week ever after the company reported promising trial results for its cancer vaccine, driving the healthcare sector higher. The article does not report any development at XLV itself.
The article highlights that the healthcare sector has been outperforming and breaking out for several months, with Moderna drawing particular attention that week, while the chip sector remains in a downturn. The body is too short to provide further details.
An analyst flagged the Health Care Sector SPDR ETF (XLV) as a likely candidate for a pullback, citing Moderna's recent strong rally as the reason. The view was part of a daily segment identifying two bearish opportunities and one bullish trade.
Healthcare ETFs, including XLV, are reaching 52-week highs driven by improving earnings, a pickup in dealmaking, a steady pace of FDA approvals, and investor demand for defensive growth. The body is a single summary sentence and offers no specific company developments or catalysts.
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.